What Allopurinol Actavis treats: main uses and benefits

Allopurinol is commonly used to help with conditions presenting with systemic or localized discomfort caused by high levels of uric acid in the body. The medicine may assist with preventing the excessive buildup of uric acid, which can cause symptoms related to inflammatory or irritative states.

This medication is commonly used for managing episodes of gout, recurrent kidney stones linked to high uric acid, and hyperuricemia (high uric acid levels) that may occur following certain types of cancer treatment. The medicine is considered relevant for easing the symptoms associated with these conditions.

A relevant clinical scenario involves its use in patients with gout, where it supports managing conditions characterized by periods of heightened symptoms. Use of this medication may be part of symptomatic management that contributes to easing the overall symptom load.

---

Quick Fact: Supports managing conditions characterized by periods of heightened symptoms

Regulatory References

1. NIH MedlinePlus Drug Information on Allopurinol

This information details the officially documented population eligibility and restrictions for Allopurinol Actavis, strictly based on regulatory labeling.

Populations Excluded from Use

Classification	Who Cannot Use the Medicine (Contraindications)
Absolute Exclusion	Patients with a known hypersensitivity to allopurinol or any excipient in the formulation.
Clinical Exclusion	Treatment of an acute attack of gout. (Therapy should begin after the attack resolves.)

Eligibility Requiring Special Caution

Population/Condition	Eligibility Status and Restrictions
Renal/Hepatic Impairment	Conditional Use. Use is permitted, but reduced doses are required due to potential drug accumulation.
Specific Ethnic Groups	Highly Restricted. Individuals of Han Chinese, Thai, or Korean descent carry a high risk for severe hypersensitivity (associated with the *HLA-B5801 allele**). Use should be avoided unless no alternative exists.
Pediatric Population	Limited Use. Safety and efficacy are not established for general use; it is typically reserved only for severe conditions like hyperuricemia secondary to malignancy or certain inherited enzyme disorders.
Pregnancy and Lactation	Restricted/Not Recommended. Use during pregnancy should occur only if clearly indicated, as safety is not fully established. Breastfeeding is generally advised against due to the excretion of the drug and its metabolite into breast milk.

Interactions with other medicines and products

This section outlines officially documented interaction patterns based on government regulatory information.

Pharmacokinetic and Pharmacodynamic Interactions

Allopurinol interacts with certain medicines by inhibiting xanthine oxidase (XOR), a key enzyme in purine metabolism. This pharmacokinetic inhibition results in significantly increased plasma concentrations of co-administered XOR substrates, such as Mercaptopurine and Azathioprine. Regulatory documents stipulate a dose reduction for these medicines when taken concurrently with Allopurinol.

Conversely, some agents, including uricosuric medicines like Probenecid and high-dose Salicylates, may decrease the therapeutic activity of Allopurinol by accelerating the clearance of its active metabolite, oxipurinol.

Pharmacodynamic interactions are also documented, including an increased risk of skin rash when Allopurinol is co-administered with Ampicillin or Amoxicillin, and an enhanced anticoagulant effect with Coumarin Anticoagulants (e.g., Warfarin).

Restrictions and Administration Rules

Co-administration with Pegloticase is a formally contraindicated combination in regulatory labeling. The combination with Didanosine is not recommended due to an increased risk of toxicity.

To prevent reduced absorption of Allopurinol, a timing separation of at least 2 to 3 hours is required when co-administering with Aluminium Hydroxide antacids. Interaction risk with Thiazide Diuretics is noted to be heightened in patients with decreased renal function.

Inhibition of the Purine Catabolism Pathway

This drug works by targeting and inhibiting the enzyme Xanthine Oxidase (XO), a key step in the breakdown of purines. The drug is metabolized into its active form, Oxypurinol, which then binds tightly to the enzyme, functionally preventing the metabolic conversion of purine precursors (Hypoxanthine and Xanthine) into Uric Acid (Urate). This inhibition modulates the rate of Uric Acid synthesis.

---

Reduction in the Systemic Uric Acid Pool

The resultant suppression of Uric Acid production leads to a systemic decrease in its plasma concentration and the overall amount present in the body. This concentration drop creates a physiological gradient that promotes the dissolution of pre-existing, solid Urate deposits within tissues back into the circulation for elimination, promoting the establishment of a lower concentration of Urate in local tissues.

---

Consequence on Reactive Oxygen Species Production

As a consequence of blocking its primary target, Xanthine Oxidase, the mechanism also attenuates a source of endogenous free radicals. The inhibition reduces the enzyme's capacity to generate Reactive Oxygen Species (ROS), which contributes to a reduction in the concentration of Reactive Oxygen Species generated by this enzyme's activity.

How to use Allopurinol Actavis: Official Administration Guidelines

Allopurinol Actavis is available for oral administration as tablets and for intravenous (IV) injection, typically reserved for patients who cannot tolerate oral therapy or are undergoing specific cancer treatments.

Dosing and Timing

Patient Group	Initial Oral Dosing	Administration Timing
Adults (Normal Renal Function)	100 mg once daily.	After meals to minimize gastric irritation.
Adults (Impaired Renal Function)	50 mg once daily, with careful, low-increment adjustments.	After meals to minimize gastric irritation.
Pediatric (Hyperuricemia/Malignancy)	10 mg/kg/day or 100 mg/m^2/ day in divided doses.	After meals

Oral doses exceeding 300 mg daily should be administered in divided doses. Dosing is adjusted weekly based on monitoring of serum uric acid levels, aiming for a concentration of le 6 mg/dL.

Procedural Instructions

• Missed Dose: If a dose is missed, do not double the dose. Skip the missed dose and resume the normal dosing schedule at the usual time.
• Fluid Intake: Patients must maintain a high, sufficient fluid intake to ensure a daily urinary output of at least 2 liters in adults, which helps prevent kidney stone formation.
• IV Preparation: The IV formulation must be reconstituted with sterile water for injection and then diluted to a final concentration no greater than 6 mg/mL using 0.9% Sodium Chloride or 5% Dextrose. Solutions containing sodium bicarbonate should be avoided. IV administration must be initiated within 10 hours of reconstitution.

Research evidence / Overview of Studies for Allopurinol Actavis

---

Evidence for Use in Gout and Chronic Hyperuricemia

Research on Allopurinol was studied to explore its role in managing hyperuricemia, a key metabolic factor associated with chronic gout. The evidence landscape primarily relies on Randomized Controlled Trials (RCTs) where participants were compared to a placebo or evaluated against alternative treatments. These trials were used in research exploring how symptoms change over time and included populations of adults diagnosed with chronic gout, including some subgroups with mild or moderate limitations in kidney function.

Studies monitored key outcomes related to systemic imbalance, primarily the serum urate concentration in the bloodstream. Research also examined outcomes describing episodic or acute changes, such as the frequency of gout flares. Long-term studies observed patterns related to changes in the size of tophi, which are the visible deposits of uric acid. Data show patterns related to the measured reduction of the urate biomarker, though the follow-up durations were limited in many older trials used for regulatory review.

---

Evidence for Acute Use in Tumor Lysis Syndrome Prevention

Allopurinol was also studied for its use in clinical situations where there is a risk of a sudden, sharp rise in uric acid. This is relevant in trials assessing short-term or episodic symptom patterns, specifically in patients receiving chemotherapy for certain types of cancer. The research examined temporary physiological imbalance, specifically monitoring the prevention of excessive levels of uric acid in the blood and urine. These studies were typically designed for short periods, focusing on episodes where symptoms become more noticeable, usually lasting only a few days to a week around the course of cancer treatment.

---

The Landscape of Evidence Gaps and Future Research

The research landscape shows patterns of consistency for the primary goals of managing uric acid levels, but evidence quality varies across studies when examining other potential applications. Exploratory research has examined Allopurinol for conditions such as cardiovascular disease and chronic kidney disease. However, findings were mixed. Large, definitive clinical trials focusing on outcomes related to systemic or functional imbalance generally showed no clear patterns related to major clinical outcomes compared to usual care. Findings suggest that while the measurement of the uric acid biomarker is well-documented, the wider certainty remains low for these exploratory uses.

Key Studies & References

1. Gout: diagnosis and management - NICE Guideline NG219 (2022)
2. Table 12, Randomized controlled trials of allopurinol versus placebo in the management of chronic gout
3. Tumor Lysis Syndrome (TLS) in Adult Patients - MD Anderson Cancer Center Protocol

Common questions about Allopurinol Actavis (FAQ)

Q: Is Allopurinol Actavis the same as allopurinol from other companies?

Allopurinol Actavis is the pharmaceutical preparation from a generic manufacturer (Actavis). This type of product is officially recognized as bioequivalent, meaning it is intended to deliver a comparable amount of the active substance, allopurinol, into the body.

Q: What is the purpose of the 'Actavis' part of the drug name?

The 'Actavis' part of the name identifies the generic manufacturer of this specific pharmaceutical preparation. Official sources indicate that this formulation is designed to provide consistent delivery of the active ingredient.

Q: Are there different strengths of Allopurinol Actavis tablets?

Yes, official product information indicates that the medicine is available in at least 100 mg and 300 mg tablet strengths.

Q: Is Allopurinol Actavis a non-steroidal anti-inflammatory drug (NSAID)?

No, this medicine is not classified as a non-steroidal anti-inflammatory drug (NSAID). According to official classification, it is categorized as an antihyperuricemic agent and a xanthine oxidase inhibitor, which works to lower uric acid.

Q: How long does it typically take for Allopurinol Actavis to start working, and when are the results checked?

While the exact time for the initial onset of effect is not precisely quantified, dosing is adjusted weekly based on monitoring. Effectiveness is typically evaluated by checking blood uric acid levels after about one month of taking a new dose.

Q: Is it okay to take Allopurinol Actavis on an empty stomach?

Administration timing is specified as after meals to help minimize potential gastric irritation. Official documents indicate administration after meals.

Q: Is it necessary to drink a lot of water while taking Allopurinol Actavis?

Official instructions state that patients are required to maintain a high, sufficient fluid intake. This requirement is in place to ensure a daily urinary output of at least 2 liters in adults, which helps prevent a specific type of kidney stone formation.

Q: What should I do if I forget to take a dose of Allopurinol Actavis?

Official instructions advise that the patient should not double the dose if a dose is missed. The prescribed procedure is to skip the missed dose and continue with the normal dosing schedule at the usual time.

Q: Is it true that Allopurinol Actavis can cause a rash, and what are the rates of common side effects?

Yes, rash is officially listed as a common side effect. The frequency for all common side effects is documented as potentially affecting up to 1 in 10 people.

Q: Can Allopurinol Actavis cause stomach upset?

Nausea, vomiting, and diarrhoea are officially documented as uncommon gastrointestinal disturbances. These reactions may affect up to 1 in 100 people.

Q: Is it normal to feel tired, or can Allopurinol Actavis affect sleep?

Drowsiness is listed as a common side effect of the medicine. Regulatory information advises caution, as drowsiness may affect alertness and sleep/wakefulness.

Q: Can Allopurinol Actavis affect my ability to drive?

Regulatory information advises that this medicine may impair your thinking or reactions. For this reason, caution should be taken when driving or performing activities requiring alertness.

Q: Is it possible to be allergic to Allopurinol Actavis?

Yes, a known hypersensitivity (allergic reaction) to allopurinol or any excipient in the formulation is listed as an absolute contraindication. This means the medicine is not intended for use by affected patients.

Q: Can older adults take Allopurinol Actavis safely?

Official documents note that an older person may be prescribed a lower dose or take the medicine at longer intervals. This adjustment is often implemented, particularly if there is reduced kidney or liver function.

Q: Is Allopurinol Actavis used to treat gout attacks, or to prevent them?

Official labeling states that the medicine is contraindicated for the treatment of an acute attack of gout. Therapy should only begin after the acute attack has fully resolved.

Q: Can this medicine make my gout symptoms worse when I first start taking it?

Yes, a temporary increase in gout attacks when first starting the medicine is a documented possibility. This is a recognized pattern during the initiation of therapy.

Q: Why is Allopurinol Actavis sometimes prescribed for kidney stones?

The medicine is officially indicated for the management of patients with recurrent calcium oxalate calculi (a type of kidney stone) whose daily uric acid excretion exceeds a specified amount.

Q: Does Allopurinol Actavis require blood tests for monitoring?

Yes, monitoring is officially recommended to ensure proper dosing and safety. This monitoring includes measuring serum uric acid levels, as well as checking complete blood count and liver and renal function periodically.

Q: Is Allopurinol Actavis safe to take if I am trying to become pregnant?

Official documents state that use during pregnancy should only occur if clearly indicated. Use is generally restricted if it is not clearly necessary. Safety during pregnancy is not fully established.

Q: Does alcohol change the way Allopurinol Actavis works?

Regulatory sources note that alcohol may increase drowsiness and other nervous system side effects. For this reason, consumption may need to be limited.

Q: Does Allopurinol Actavis interact with warfarin or other blood thinners?

Yes, an enhanced anticoagulant effect is documented when Allopurinol Actavis is taken with Coumarin Anticoagulants, such as Warfarin. This interaction requires close attention.

Q: Does Allopurinol Actavis have any known severe interactions?

Yes, co-administration with Pegloticase is a formally documented contraindicated combination in regulatory labeling. The combination of these two medicines is not permitted.

Q: Does Allopurinol Actavis interact with blood pressure medicine?

A heightened interaction risk is noted with Thiazide Diuretics, a common type of blood pressure medicine, particularly in patients with decreased kidney function.

Q: Is there a link between Allopurinol Actavis and liver function?

Abnormal liver function tests are listed as an uncommon side effect of the medicine. In rare cases, more serious reactions like Hepatitis have also been documented.

Q: How long does Allopurinol Actavis stay in my system?

The active substance is rapidly processed by the body into its active metabolite, oxypurinol. This metabolite, which also lowers uric acid, has a half-life of approximately 15 hours.

Q: Can children or adolescents use Allopurinol Actavis?

Use is generally not established for general pediatric use. The medicine is typically reserved for severe, specific conditions like hyperuricemia secondary to malignancy or certain inherited enzyme disorders.

Q: Are there any studies about the long-term use of Allopurinol Actavis?

Research has observed long-term patterns related to changes in the size of tophi (uric acid deposits). However, regulatory documents note that the follow-up durations in many older trials were limited.

Q: What are the main findings from clinical trials of Allopurinol Actavis?

Main findings relate to the measured reduction of the serum urate concentration in the bloodstream. They also describe patterns related to the frequency of gout flares and changes in the size of tophi.

Q: Do studies support the use of Allopurinol Actavis for people who have had a heart attack?

Exploratory research has examined the drug for conditions like cardiovascular disease. However, large clinical trials in this area generally showed mixed findings and no clear patterns related to major clinical outcomes compared to usual care.

Q: What temperature should Allopurinol Actavis be stored at?

Official storage requirements state that the product should not be stored above 25 C. To maintain stability, the product is required to be kept in the original, tightly closed container.

Q: Is Allopurinol Actavis an antibiotic?

No, Allopurinol Actavis is not an antibiotic. It is officially classified as an antihyperuricemic agent and a xanthine oxidase inhibitor, which is a type of medicine used to lower uric acid.

Official Storage and Disposal Instructions

Allopurinol tablets must be stored according to specific regulatory requirements to ensure stability and safety. The product should not be stored above 25 C. To protect the medicine, keep the tablets in their original container or package and ensure the container is tightly closed.

Storage Condition	Requirement
Temperature Limit	Do not store above 25 C
Packaging	Keep in original, tightly closed container/package
Shelf-Life	2 to 3 years, depending on packaging type

For disposal, do not flush allopurinol down the toilet or pour it down a drain unless specifically instructed by a government authority. Follow the standard drug disposal procedure: mix the medicine with an unappealing substance, such as used coffee grounds or kitty litter, place the mixture into a sealed bag or container, and dispose of it in the household trash. Before discarding the empty original container, scratch out all identifying personal information on the label.